Moderna, Inc. (MRNA) Stock Competitors & Peer Comparison
See (MRNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRNA | $51.53 | +5.03% | 20.4B | -6.33 | -$8.14 | N/A |
| NVO | $43.74 | +4.14% | 194.4B | 10.24 | $4.27 | +4.27% |
| VRTX | $441.75 | +3.13% | 112.1B | 26.25 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $628.66 | +1.57% | 64.8B | 15.34 | $40.97 | +0.59% |
| ARGX | $842.27 | +3.58% | 52.1B | 37.38 | $22.53 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $303.64 | +3.78% | 40.5B | 76.10 | $3.99 | N/A |
| RVMD | $155.52 | -0.30% | 33.1B | -21.87 | -$7.11 | N/A |
| RPRX | $55.02 | +0.09% | 23.7B | 28.96 | $1.90 | +1.65% |
Stock Comparison
MRNA vs NVO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, NVO has a market cap of 194.4B. Regarding current trading prices, MRNA is priced at $51.53, while NVO trades at $43.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas NVO's P/E ratio is 10.24. In terms of profitability, MRNA's ROE is -0.37%, compared to NVO's ROE of +0.66%. Regarding short-term risk, MRNA is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NVO's competition here
MRNA vs VRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, VRTX has a market cap of 112.1B. Regarding current trading prices, MRNA is priced at $51.53, while VRTX trades at $441.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas VRTX's P/E ratio is 26.25. In terms of profitability, MRNA's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRTX's competition here
MRNA vs VRNA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRNA is priced at $51.53, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRNA's ROE is -0.37%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRNA's competition here
MRNA vs REGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, REGN has a market cap of 64.8B. Regarding current trading prices, MRNA is priced at $51.53, while REGN trades at $628.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas REGN's P/E ratio is 15.34. In terms of profitability, MRNA's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MRNA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check REGN's competition here
MRNA vs ARGX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ARGX has a market cap of 52.1B. Regarding current trading prices, MRNA is priced at $51.53, while ARGX trades at $842.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ARGX's P/E ratio is 37.38. In terms of profitability, MRNA's ROE is -0.37%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, MRNA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ARGX's competition here
MRNA vs SGEN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRNA is priced at $51.53, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRNA's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SGEN's competition here
MRNA vs ALNY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ALNY has a market cap of 40.5B. Regarding current trading prices, MRNA is priced at $51.53, while ALNY trades at $303.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ALNY's P/E ratio is 76.10. In terms of profitability, MRNA's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MRNA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALNY's competition here
MRNA vs RVMD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RVMD has a market cap of 33.1B. Regarding current trading prices, MRNA is priced at $51.53, while RVMD trades at $155.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RVMD's P/E ratio is -21.87. In terms of profitability, MRNA's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RVMD's competition here
MRNA vs RPRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, MRNA is priced at $51.53, while RPRX trades at $55.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RPRX's P/E ratio is 28.96. In terms of profitability, MRNA's ROE is -0.37%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, MRNA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RPRX's competition here
MRNA vs UTHR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, MRNA is priced at $51.53, while UTHR trades at $547.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas UTHR's P/E ratio is 20.25. In terms of profitability, MRNA's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check UTHR's competition here
MRNA vs INSM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, MRNA is priced at $51.53, while INSM trades at $104.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas INSM's P/E ratio is -18.22. In terms of profitability, MRNA's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MRNA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check INSM's competition here
MRNA vs BNTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BNTX has a market cap of 22.7B. Regarding current trading prices, MRNA is priced at $51.53, while BNTX trades at $89.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BNTX's P/E ratio is -15.16. In terms of profitability, MRNA's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BNTX's competition here
MRNA vs ROIV Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ROIV has a market cap of 21.2B. Regarding current trading prices, MRNA is priced at $51.53, while ROIV trades at $29.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ROIV's P/E ratio is -54.65. In terms of profitability, MRNA's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ROIV's competition here
MRNA vs INCY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, INCY has a market cap of 20.2B. Regarding current trading prices, MRNA is priced at $51.53, while INCY trades at $101.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas INCY's P/E ratio is 14.30. In terms of profitability, MRNA's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MRNA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check INCY's competition here
MRNA vs BGNE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRNA is priced at $51.53, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRNA's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MRNA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BGNE's competition here
MRNA vs DNA-WT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRNA is priced at $51.53, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MRNA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check DNA-WT's competition here
MRNA vs NBIX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, MRNA is priced at $51.53, while NBIX trades at $167.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas NBIX's P/E ratio is 25.75. In terms of profitability, MRNA's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MRNA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NBIX's competition here
MRNA vs GMAB Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, GMAB has a market cap of 15.2B. Regarding current trading prices, MRNA is priced at $51.53, while GMAB trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas GMAB's P/E ratio is 18.88. In terms of profitability, MRNA's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MRNA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check GMAB's competition here
MRNA vs JAZZ Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, MRNA is priced at $51.53, while JAZZ trades at $240.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas JAZZ's P/E ratio is 2183.00. In terms of profitability, MRNA's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MRNA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check JAZZ's competition here
MRNA vs ASND Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, MRNA is priced at $51.53, while ASND trades at $218.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ASND's P/E ratio is 24.81. In terms of profitability, MRNA's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MRNA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ASND's competition here
MRNA vs EXEL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, EXEL has a market cap of 13.2B. Regarding current trading prices, MRNA is priced at $51.53, while EXEL trades at $52.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas EXEL's P/E ratio is 17.38. In terms of profitability, MRNA's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check EXEL's competition here
MRNA vs BBIO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, MRNA is priced at $51.53, while BBIO trades at $67.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BBIO's P/E ratio is -18.00. In terms of profitability, MRNA's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BBIO's competition here
MRNA vs KRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRNA is priced at $51.53, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRNA's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KRTX's competition here
MRNA vs IONS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, MRNA is priced at $51.53, while IONS trades at $75.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas IONS's P/E ratio is -37.38. In terms of profitability, MRNA's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MRNA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IONS's competition here
MRNA vs AXSM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, AXSM has a market cap of 11.9B. Regarding current trading prices, MRNA is priced at $51.53, while AXSM trades at $231.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas AXSM's P/E ratio is -62.06. In terms of profitability, MRNA's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MRNA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AXSM's competition here
MRNA vs SMMT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, SMMT has a market cap of 11.5B. Regarding current trading prices, MRNA is priced at $51.53, while SMMT trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas SMMT's P/E ratio is -9.33. In terms of profitability, MRNA's ROE is -0.37%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MRNA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SMMT's competition here
MRNA vs MDGL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MDGL has a market cap of 11.4B. Regarding current trading prices, MRNA is priced at $51.53, while MDGL trades at $492.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MDGL's P/E ratio is -36.48. In terms of profitability, MRNA's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, MRNA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MDGL's competition here
MRNA vs RNAM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRNA is priced at $51.53, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRNA's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MRNA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RNAM's competition here
MRNA vs BMRN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, MRNA is priced at $51.53, while BMRN trades at $56.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BMRN's P/E ratio is 40.63. In terms of profitability, MRNA's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MRNA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BMRN's competition here
MRNA vs ARWR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, MRNA is priced at $51.53, while ARWR trades at $75.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ARWR's P/E ratio is -33.11. In terms of profitability, MRNA's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MRNA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ARWR's competition here
MRNA vs RXDX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRNA is priced at $51.53, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRNA's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RXDX's competition here
MRNA vs KRYS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, MRNA is priced at $51.53, while KRYS trades at $307.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas KRYS's P/E ratio is 41.15. In terms of profitability, MRNA's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KRYS's competition here
MRNA vs CYTK Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, MRNA is priced at $51.53, while CYTK trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CYTK's P/E ratio is -10.55. In terms of profitability, MRNA's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MRNA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CYTK's competition here
MRNA vs IMGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $51.53, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRNA's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IMGN's competition here
MRNA vs HALO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, HALO has a market cap of 8.5B. Regarding current trading prices, MRNA is priced at $51.53, while HALO trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas HALO's P/E ratio is 25.12. In terms of profitability, MRNA's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MRNA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check HALO's competition here
MRNA vs BPMC Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRNA is priced at $51.53, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRNA's ROE is -0.37%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, MRNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BPMC's competition here
MRNA vs TECH Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, MRNA is priced at $51.53, while TECH trades at $53.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas TECH's P/E ratio is 75.99. In terms of profitability, MRNA's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MRNA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TECH's competition here
MRNA vs CERE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $51.53, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRNA's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CERE's competition here
MRNA vs CORT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CORT has a market cap of 8B. Regarding current trading prices, MRNA is priced at $51.53, while CORT trades at $74.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CORT's P/E ratio is 213.91. In terms of profitability, MRNA's ROE is -0.37%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MRNA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CORT's competition here
MRNA vs IBRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, MRNA is priced at $51.53, while IBRX trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas IBRX's P/E ratio is -8.58. In terms of profitability, MRNA's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MRNA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IBRX's competition here
MRNA vs MTSR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $51.53, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRNA's ROE is -0.37%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MRNA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MTSR's competition here
MRNA vs ALKS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ALKS has a market cap of 7.2B. Regarding current trading prices, MRNA is priced at $51.53, while ALKS trades at $43.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ALKS's P/E ratio is 48.20. In terms of profitability, MRNA's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MRNA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALKS's competition here
MRNA vs PCVX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, PCVX has a market cap of 7B. Regarding current trading prices, MRNA is priced at $51.53, while PCVX trades at $48.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas PCVX's P/E ratio is -7.08. In terms of profitability, MRNA's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PCVX's competition here
MRNA vs NUVL Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, NUVL has a market cap of 6.9B. Regarding current trading prices, MRNA is priced at $51.53, while NUVL trades at $94.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas NUVL's P/E ratio is -15.51. In terms of profitability, MRNA's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NUVL's competition here
MRNA vs ABVX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ABVX has a market cap of 6.9B. Regarding current trading prices, MRNA is priced at $51.53, while ABVX trades at $104.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ABVX's P/E ratio is -19.54. In terms of profitability, MRNA's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MRNA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check ABVX's competition here
MRNA vs MRUS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRNA is priced at $51.53, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRNA's ROE is -0.37%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MRNA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRUS's competition here
MRNA vs ACLX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $51.53, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRNA's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MRNA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACLX's competition here
MRNA vs IMVT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $51.53, while IMVT trades at $32.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas IMVT's P/E ratio is -11.79. In terms of profitability, MRNA's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MRNA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IMVT's competition here
MRNA vs PTGX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $51.53, while PTGX trades at $102.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas PTGX's P/E ratio is -56.79. In terms of profitability, MRNA's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MRNA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check PTGX's competition here
MRNA vs RETA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $51.53, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRNA's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RETA's competition here
MRNA vs LEGN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, LEGN has a market cap of 6.3B. Regarding current trading prices, MRNA is priced at $51.53, while LEGN trades at $34.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas LEGN's P/E ratio is -24.78. In terms of profitability, MRNA's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MRNA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LEGN's competition here
MRNA vs TGTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, TGTX has a market cap of 6.2B. Regarding current trading prices, MRNA is priced at $51.53, while TGTX trades at $40.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas TGTX's P/E ratio is 14.17. In terms of profitability, MRNA's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MRNA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TGTX's competition here
MRNA vs CNTA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, MRNA is priced at $51.53, while CNTA trades at $39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CNTA's P/E ratio is -22.36. In terms of profitability, MRNA's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CNTA's competition here
MRNA vs KYMR Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, KYMR has a market cap of 6.1B. Regarding current trading prices, MRNA is priced at $51.53, while KYMR trades at $74.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas KYMR's P/E ratio is -20.82. In terms of profitability, MRNA's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MRNA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KYMR's competition here
MRNA vs RYTM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, MRNA is priced at $51.53, while RYTM trades at $87.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RYTM's P/E ratio is -27.99. In terms of profitability, MRNA's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MRNA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYTM's competition here
MRNA vs PTCT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, MRNA is priced at $51.53, while PTCT trades at $70.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas PTCT's P/E ratio is -27.81. In terms of profitability, MRNA's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MRNA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PTCT's competition here
MRNA vs BLTE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BLTE has a market cap of 5.8B. Regarding current trading prices, MRNA is priced at $51.53, while BLTE trades at $144.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BLTE's P/E ratio is -56.87. In terms of profitability, MRNA's ROE is -0.37%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, MRNA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check BLTE's competition here
MRNA vs APGE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, APGE has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $51.53, while APGE trades at $90.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas APGE's P/E ratio is -20.99. In terms of profitability, MRNA's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MRNA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check APGE's competition here
MRNA vs CDTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $51.53, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRNA's ROE is -0.37%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CDTX's competition here
MRNA vs COGT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $51.53, while COGT trades at $32.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas COGT's P/E ratio is -15.11. In terms of profitability, MRNA's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check COGT's competition here
MRNA vs PRAX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, PRAX has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $51.53, while PRAX trades at $264.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas PRAX's P/E ratio is -19.78. In terms of profitability, MRNA's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MRNA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check PRAX's competition here
MRNA vs LQDA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, LQDA has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $51.53, while LQDA trades at $62.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas LQDA's P/E ratio is 367.88. In terms of profitability, MRNA's ROE is -0.37%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MRNA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check LQDA's competition here
MRNA vs ABCM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $51.53, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRNA's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ABCM's competition here
MRNA vs ISEE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $51.53, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRNA's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRNA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ISEE's competition here
MRNA vs CRSP Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $51.53, while CRSP trades at $56.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CRSP's P/E ratio is -9.23. In terms of profitability, MRNA's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MRNA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CRSP's competition here
MRNA vs SRRK Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, MRNA is priced at $51.53, while SRRK trades at $45.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas SRRK's P/E ratio is -13.13. In terms of profitability, MRNA's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MRNA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SRRK's competition here
MRNA vs APLS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $51.53, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRNA's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check APLS's competition here
MRNA vs FBIOX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $51.53, while FBIOX trades at $24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas FBIOX's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, MRNA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check FBIOX's competition here
MRNA vs CGON Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CGON has a market cap of 4.9B. Regarding current trading prices, MRNA is priced at $51.53, while CGON trades at $56.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CGON's P/E ratio is -23.97. In terms of profitability, MRNA's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MRNA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CGON's competition here
MRNA vs CAI Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, MRNA is priced at $51.53, while CAI trades at $17.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CAI's P/E ratio is -6.26. In terms of profitability, MRNA's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MRNA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CAI's competition here
MRNA vs TERN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MRNA is priced at $51.53, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRNA's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MRNA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TERN's competition here
MRNA vs SYRE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, SYRE has a market cap of 4.7B. Regarding current trading prices, MRNA is priced at $51.53, while SYRE trades at $78.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas SYRE's P/E ratio is -36.99. In terms of profitability, MRNA's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MRNA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check SYRE's competition here
MRNA vs LGND Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, MRNA is priced at $51.53, while LGND trades at $235.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas LGND's P/E ratio is 30.76. In terms of profitability, MRNA's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MRNA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LGND's competition here
MRNA vs MIRM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, MRNA is priced at $51.53, while MIRM trades at $92.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MIRM's P/E ratio is -6.80. In terms of profitability, MRNA's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MRNA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MIRM's competition here
MRNA vs FOLD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $51.53, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRNA's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MRNA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check FOLD's competition here
MRNA vs CELC Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $51.53, while CELC trades at $92.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CELC's P/E ratio is -23.69. In terms of profitability, MRNA's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MRNA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CELC's competition here
MRNA vs AKRO Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $51.53, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRNA's ROE is -0.37%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AKRO's competition here
MRNA vs ALPN Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $51.53, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRNA's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALPN's competition here
MRNA vs TVTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, TVTX has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $51.53, while TVTX trades at $46.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas TVTX's P/E ratio is -92.34. In terms of profitability, MRNA's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MRNA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check TVTX's competition here
MRNA vs OPT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $51.53, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRNA's ROE is -0.37%, compared to OPT's ROE of +1.09%. Regarding short-term risk, MRNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check OPT's competition here
MRNA vs MANE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $51.53, while MANE trades at $101.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MANE's P/E ratio is -38.18. In terms of profitability, MRNA's ROE is -0.37%, compared to MANE's ROE of -0.95%. Regarding short-term risk, MRNA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check MANE's competition here
MRNA vs XENE Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $51.53, while XENE trades at $52.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas XENE's P/E ratio is -11.27. In terms of profitability, MRNA's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MRNA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check XENE's competition here
MRNA vs ERAS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ERAS has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $51.53, while ERAS trades at $13.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ERAS's P/E ratio is -14.27. In terms of profitability, MRNA's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MRNA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check ERAS's competition here
MRNA vs MRTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $51.53, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRNA's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRNA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRTX's competition here
MRNA vs EWTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, MRNA is priced at $51.53, while EWTX trades at $37.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas EWTX's P/E ratio is -22.43. In terms of profitability, MRNA's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check EWTX's competition here
MRNA vs VCYT Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, VCYT has a market cap of 4B. Regarding current trading prices, MRNA is priced at $51.53, while VCYT trades at $49.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas VCYT's P/E ratio is 46.24. In terms of profitability, MRNA's ROE is -0.37%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, MRNA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VCYT's competition here
MRNA vs CPRX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $51.53, while CPRX trades at $31.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CPRX's P/E ratio is 18.09. In terms of profitability, MRNA's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CPRX's competition here
MRNA vs NAMS Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $51.53, while NAMS trades at $32.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas NAMS's P/E ratio is -18.35. In terms of profitability, MRNA's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NAMS's competition here
MRNA vs RYZB Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $51.53, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRNA's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYZB's competition here
MRNA vs CBAY Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $51.53, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRNA's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CBAY's competition here
MRNA vs ACAD Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $51.53, while ACAD trades at $21.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas ACAD's P/E ratio is 9.83. In terms of profitability, MRNA's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACAD's competition here
MRNA vs KNSA Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $51.53, while KNSA trades at $49.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas KNSA's P/E ratio is 54.10. In terms of profitability, MRNA's ROE is -0.37%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, MRNA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check KNSA's competition here
MRNA vs CRNX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $51.53, while CRNX trades at $34.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas CRNX's P/E ratio is -6.74. In terms of profitability, MRNA's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRNA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CRNX's competition here
MRNA vs SWTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $51.53, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MRNA's ROE is -0.37%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SWTX's competition here
MRNA vs DNTH Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $51.53, while DNTH trades at $84.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas DNTH's P/E ratio is -19.88. In terms of profitability, MRNA's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MRNA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DNTH's competition here
MRNA vs VKTX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, MRNA is priced at $51.53, while VKTX trades at $29.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas VKTX's P/E ratio is -7.18. In terms of profitability, MRNA's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MRNA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VKTX's competition here
MRNA vs BEAM Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, BEAM has a market cap of 3.4B. Regarding current trading prices, MRNA is priced at $51.53, while BEAM trades at $32.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas BEAM's P/E ratio is -67.00. In terms of profitability, MRNA's ROE is -0.37%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, MRNA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check BEAM's competition here
MRNA vs TLX Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, MRNA is priced at $51.53, while TLX trades at $9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas TLX's P/E ratio is -477.00. In terms of profitability, MRNA's ROE is -0.37%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MRNA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check TLX's competition here
MRNA vs DNLI Comparison June 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 20.4B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, MRNA is priced at $51.53, while DNLI trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -6.33, whereas DNLI's P/E ratio is -6.99. In terms of profitability, MRNA's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MRNA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DNLI's competition here